Outlook Shares Plunges After Raising $500M Via Equity Offering Issued At 20% Discount
Outlook Therapeutics Inc (NASDAQ: OTLK) has increased the size of the previously announced
28 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Engine Gaming and Media, Inc. (NASDAQ: GAME) rose 51% to $4.80 in pre-market trading after the company reported Q4 2021 and FY21 revenue was higher year over year.
Outlook Therapeutics Sponsored Study Titled ‘A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders (NORSE SEVEN)’ Posted To ClinicalTrials.gov; Study Not Recruit…
https://clinicaltrials.gov/ct2/show/NCT05112861
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
Outlook Therapeutics To Present At The 2021 American Society Of Retina Specialists Annual Meeting
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Suber
Outlook Therapeutics Reports 12-Month Safety Data From Pivotal Phase 3 NORSE TWO Trial: ‘Full year data reinforce strong safety profile consistent with previous trials…’
Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab
Full data to be presented at American Academy of
Outlook Therapeutics: Q3 Earnings Insights
Shares of Outlook Therapeutics (NASDAQ:OTLK) moved higher by 2.8% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were down 133.33% year over year to ($0.07), which were in line with the estimate of ($0.07).
Outlook Therapeutics Q3 EPS $(0.07) Down From $(0.03) YoY
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.07) per share. This is a 133.33 percent decrease over losses of $(0.03) per share from the same period last year.
Outlook Therapeutics Shares See Volume, Traders Circulate TipRanks Article Titled, ‘Outlook Therapeutic Stock Set to See Big Gains, Says Analyst’
https://www.tipranks.com/news/article/outlook-therapeutic-stock-set-to-see-big-gains-says-analyst/